Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the 9^th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:45 pm ET at the Lotte New York Palace.

About Cadent Therapeutics

Cadent Therapeutics is creating therapies for the treatment of movement, mood, and cognitive disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators to treat spinocerebellar ataxia, essential tremor, and schizophrenia. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.

Contacts

Investors:
Maeve Conneighton, [email protected]
212.600.1902

Media:
David Rosen, [email protected]
212.600.1902